Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
CDKN2A deletion
i
Other names:
CDKN2A, ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf, Cyclin-dependent kinase inhibitor 2A
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
1029
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
CDKN2A deletion
B Acute Lymphoblastic Leukemia
CDKN2A deletion
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
CDKN2A deletion
Mantle Cell Lymphoma
CDKN2A deletion
Mantle Cell Lymphoma
ibrutinib
Resistant: C3 – Early Trials
ibrutinib
Resistant
:
C3
ibrutinib
Resistant: C3 – Early Trials
ibrutinib
Resistant
:
C3
CDKN2A deletion
Acute Lymphocytic Leukemia
CDKN2A deletion
Acute Lymphocytic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
CDKN2A deletion
Melanoma
CDKN2A deletion
Melanoma
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
CDKN2A deletion
Gallbladder Cancer
CDKN2A deletion
Gallbladder Cancer
palbociclib
Resistant: C3 – Early Trials
palbociclib
Resistant
:
C3
palbociclib
Resistant: C3 – Early Trials
palbociclib
Resistant
:
C3
CDKN2A deletion
Glioma
CDKN2A deletion
Glioma
vincristine + lomustine + procarbazine hydrochloride
Resistant: C3 – Early Trials
vincristine + lomustine + procarbazine hydrochloride
Resistant
:
C3
vincristine + lomustine + procarbazine hydrochloride
Resistant: C3 – Early Trials
vincristine + lomustine + procarbazine hydrochloride
Resistant
:
C3
CDKN2A deletion
Hepatocellular Cancer
CDKN2A deletion
Hepatocellular Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
CDKN2A deletion
Melanoma
CDKN2A deletion
Melanoma
palbociclib
Sensitive: C3 – Early Trials
palbociclib
Sensitive
:
C3
palbociclib
Sensitive: C3 – Early Trials
palbociclib
Sensitive
:
C3
CDKN2A deletion
Pancreatic Cancer
CDKN2A deletion
Pancreatic Cancer
palbociclib
Resistant: C3 – Early Trials
palbociclib
Resistant
:
C3
palbociclib
Resistant: C3 – Early Trials
palbociclib
Resistant
:
C3
CDKN2A deletion
Gastric Adenocarcinoma
CDKN2A deletion
Gastric Adenocarcinoma
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
CDKN2A deletion
Diffuse Large B Cell Lymphoma
CDKN2A deletion
Diffuse Large B Cell Lymphoma
T-lymphocyte cell therapy
Resistant: C3 – Early Trials
T-lymphocyte cell therapy
Resistant
:
C3
T-lymphocyte cell therapy
Resistant: C3 – Early Trials
T-lymphocyte cell therapy
Resistant
:
C3
CDKN2A deletion
Prolymphocytic Leukemia
CDKN2A deletion
Prolymphocytic Leukemia
alemtuzumab
Resistant: C4 – Case Studies
alemtuzumab
Resistant
:
C4
alemtuzumab
Resistant: C4 – Case Studies
alemtuzumab
Resistant
:
C4
CDKN2A deletion
Estrogen Receptor Positive Breast Cancer
CDKN2A deletion
Estrogen Receptor Positive Breast Cancer
palbociclib + VRx-510
Sensitive: D – Preclinical
palbociclib + VRx-510
Sensitive
:
D
palbociclib + VRx-510
Sensitive: D – Preclinical
palbociclib + VRx-510
Sensitive
:
D
CDKN2A deletion
Estrogen Receptor Positive Breast Cancer
CDKN2A deletion
Estrogen Receptor Positive Breast Cancer
ribociclib + VRx-510
Sensitive: D – Preclinical
ribociclib + VRx-510
Sensitive
:
D
ribociclib + VRx-510
Sensitive: D – Preclinical
ribociclib + VRx-510
Sensitive
:
D
CDKN2A deletion
Ewing Sarcoma
CDKN2A deletion
Ewing Sarcoma
ASP7487
Sensitive: D – Preclinical
ASP7487
Sensitive
:
D
ASP7487
Sensitive: D – Preclinical
ASP7487
Sensitive
:
D
CDKN2A deletion
Ewing Sarcoma
CDKN2A deletion
Ewing Sarcoma
palbociclib
Sensitive: D – Preclinical
palbociclib
Sensitive
:
D
palbociclib
Sensitive: D – Preclinical
palbociclib
Sensitive
:
D
CDKN2A deletion
Renal Cell Carcinoma
CDKN2A deletion
Renal Cell Carcinoma
temsirolimus
Sensitive: D – Preclinical
temsirolimus
Sensitive
:
D
temsirolimus
Sensitive: D – Preclinical
temsirolimus
Sensitive
:
D
CDKN2A deletion
Pancreatic Ductal Adenocarcinoma
CDKN2A deletion
Pancreatic Ductal Adenocarcinoma
BET inhibitor + CDK inhibitor
Sensitive: D – Preclinical
BET inhibitor + CDK inhibitor
Sensitive
:
D
BET inhibitor + CDK inhibitor
Sensitive: D – Preclinical
BET inhibitor + CDK inhibitor
Sensitive
:
D
CDKN2A deletion
HER2 Positive Breast Cancer
CDKN2A deletion
HER2 Positive Breast Cancer
abemaciclib + tucatinib
Sensitive: D – Preclinical
abemaciclib + tucatinib
Sensitive
:
D
abemaciclib + tucatinib
Sensitive: D – Preclinical
abemaciclib + tucatinib
Sensitive
:
D
CDKN2A deletion
Pancreatic Ductal Adenocarcinoma
CDKN2A deletion
Pancreatic Ductal Adenocarcinoma
palbociclib + JQ-1
Sensitive: D – Preclinical
palbociclib + JQ-1
Sensitive
:
D
palbociclib + JQ-1
Sensitive: D – Preclinical
palbociclib + JQ-1
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login